专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2003063903A2 MODULATION OF T LYMPHOCYTES USING DP IV INHIBITORS 审中-公开
标题翻译：使用DP IV抑制剂对T淋巴细胞的调节
公开(公告)号：WO2003063903A2
公开(公告)日：2003-08-07
申请号：PCT/EP2003/001044
申请日：2003-02-03
申请人： PROBIODRUG AG , HOFFMANN, Torsten , HILDEBRANDT, Martin , DEMUTH, Hans-Ulrich
发明人： HOFFMANN, Torsten , HILDEBRANDT, Martin , DEMUTH, Hans-Ulrich
IPC分类号： A61K45/00
CPC分类号： A61K31/40
摘要： The present invention discloses a method for therapeutically treating mammals, including but not limited to humans, to modulate immune responses via modulation of surface expression of co-stimulatory antigens on T lymphocytes. oral administration of a DP IV inhibitor causes a potent immunosuppressive effect. This immunosuppressive effect of DP IV inhibitors is exerted by an enhancement of CTLA-4 surface expression, with simultaneous inhibition of CD28 surface expression, on T cells. Furthermore, the present invention discloses preparation of a medicament, comprising one or more inhibitors of dipeptidyl peptidase enzymatic activity, for the treatment of immune disorders such as allograft rejection or autoimmune disease.
摘要翻译：本发明公开了一种用于治疗性治疗哺乳动物（包括但不限于人）通过调节T淋巴细胞上的共刺激抗原表面表达来调节免疫应答的方法。 DP IV抑制剂的口服给药会产生有效的免疫抑制作用。 DP IV抑制剂的这种免疫抑制作用是通过增强CTLA-4表面表达，同时抑制CD28表面表达在T细胞上发挥的。此外，本发明公开了一种药物的制备，其包含一种或多种二肽基肽酶酶活性抑制剂，用于治疗免疫疾病如同种异体移植排斥或自身免疫性疾病。

62. 发明申请

WO03002596A3 USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS 审中-公开
标题翻译：作为治疗神经病的治疗药物，可以将DIPEPTIDYL PEPTIDASE IV抑制剂
公开(公告)号：WO03002596A3
公开(公告)日：2003-07-31
申请号：PCT/EP0207133
申请日：2002-06-27
申请人： PROBIODRUG AG , DEMUTH HANS-ULRICH , HOFFMANN TORSTEN , HEISER ULRICH , GLUND KONRAD , VON HOERSTEN STEPHAN
发明人： DEMUTH HANS-ULRICH , HOFFMANN TORSTEN , HEISER ULRICH , GLUND KONRAD , VON HOERSTEN STEPHAN
IPC分类号： C07D295/18 , A61K31/13 , A61K31/40 , A61K31/426 , A61K35/00 , A61K38/00 , A61K38/04 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/00 , A61P3/04 , A61P3/10 , A61P9/10 , A61P17/00 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/28 , A61P35/00 , A61P35/04 , A61P37/00 , A61P37/06 , A61P43/00 , C07D207/04 , C07D207/06 , C07D277/04 , C07K5/062 , C07K5/08 , C07K5/083 , C07K5/087 , C07K5/10 , C07K7/06 , C07K7/08
CPC分类号： C07D295/185 , A61K38/04 , A61K38/06 , A61K38/07 , A61K38/08 , C07D207/04 , C07D277/04 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0812 , C07K7/06
摘要： The present invention provides a new use of DPIV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in treating conditions mediated by DPIV or DPIV-Iike enzymes, such as immune, autoimmune or central nervous system disorder selected from the group consisting of strokes, tumors, ischemia, Parkinson's disease and migraines. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of multiple sclerosis.
摘要翻译：本发明提供DPIV-抑制剂的新用途。本发明的化合物及其相应的药学上可接受的酸加成盐形式可用于治疗由DPIV或DPIV-Iike酶介导的病症，例如选自中风，肿瘤的免疫，自身免疫或中枢神经系统疾病，缺血，帕金森病和偏头痛。在更优选的实施方案中，本发明的化合物可用于治疗多发性硬化。

63. 发明申请

WO2003022871A3 PEPTIDES HAVING A C- TERMINAL HYDROXYLAMINO GROUP AS INHIBITORS OF DIPEPTIDYL PEPTIDASE I 审中-公开
公开(公告)号：WO2003022871A3
公开(公告)日：2003-03-20
申请号：PCT/EP2002/010020
申请日：2002-09-06
申请人： PROBIODRUG AG , DEMUTH, Hans-Ulrich , HEISER, Ulrich , NIESTROJ, André
发明人： DEMUTH, Hans-Ulrich , HEISER, Ulrich , NIESTROJ, André
IPC分类号： C07K5/06
摘要： The present invention relates to new compounds, namely peptides having a C- terminal carbonyl- (or thiocarbonyl)- oxy- amide, that act as specific inhibitors of the cysteine protease dipeptidyl peptidase I (OP I). Those compounds are represented by the general formula (I) and the pharmaceutical salts thereof, in which R is an acyl-residue including urethane and, peptide, or a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 carbocyclic, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, all of the above residues may be optionally substituted, or is H, AS is an amino acid or a peptide mimetic thereof. The amino acid is peptide bound with R and R' is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5 - C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, whereas the heterocycloalkyl, heterocycloalkenyl, heteroaryl, heterocyclic residue can have up to 6 hetero ring atoms, an amino acid or a peptide mimetic thereof, all of the above residues my be optionally substituted, or is H. E is O or S.

64. 发明申请

WO2003022871A2 NOVEL INHIBITORS OF DIPEPTIDYL PEPTIDASE I 审中-公开
标题翻译：脯氨酸肽的新型抑制剂I
公开(公告)号：WO2003022871A2
公开(公告)日：2003-03-20
申请号：PCT/EP2002/010020
申请日：2002-09-06
申请人： PROBIODRUG AG , DEMUTH, Hans-Ulrich , HEISER, Ulrich , NIESTROJ, André
发明人： DEMUTH, Hans-Ulrich , HEISER, Ulrich , NIESTROJ, André
IPC分类号： C07K5/00
CPC分类号： C07K5/06
摘要： The present invention relates to new compounds that act as specific inhibitors of the cysteine protease dipeptidyl peptidase I (OP I). Those compounds are represented by the general formula (I) and the pharmaceutical salts thereof, in which R is an acyl-residue including urethane and, peptide, or a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 carbocyclic, C 5 -C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, all of the above residues may be optionally substituted, or is H, AS is an amino acid or a peptide mimetic thereof. The amino acid is peptide bound with R and R' is a branched or unbranched C 1 -C 9 alkyl chain, a branched or unbranched C 2 -C 9 alkenyl chain, a branched or unbranched C 2 -C 9 alkynyl chain, a C 3 -C 9 cycloalkyl, C 4 -C 9 cycloalkenyl, C 2 -C 9 heterocycloalkyl, C 3 -C 9 heterocycloalkenyl, C 5 - C 14 aryl, C 3 -C 9 heteroaryl, C 3 -C 9 heterocyclic, whereas the heterocycloalkyl, heterocycloalkenyl, heteroaryl, heterocyclic residue can have up to 6 hetero ring atoms, an amino acid or a peptide mimetic thereof, all of the above residues my be optionally substituted, or is H.
摘要翻译：本发明涉及作为半胱氨酸蛋白酶二肽基肽酶I（OP I）的特异性抑制剂的新化合物。那些化合物由通式（I）及其药用盐表示，其中R是包括氨基甲酸酯和肽，或支链或非支链C 1 -C 9烷基链的酰基残基，支链或非支链C 2 -C 9链烯基链，支链或非支链C 2 -C 9炔基链，C 3 -C 9环烷基，C 4 -C 9碳环，C 5 -C 14芳基，C 3 -C 9杂芳基，C 3 -C 9杂环，所有上述残基均可任选被取代，或 H，AS是氨基酸或其模拟肽。氨基酸是与R结合的肽，R'是支链或非支链C1-C9烷基链，支链或非支链C2-C9烯基链，支链或非支链C2-C9炔基链，C3-C9环烷基，C4- C 9环烯基，C 2 -C 9杂环烷基，C 3 -C 9杂环烯基，C 5 -C 14芳基，C 3 -C 9杂芳基，C 3 -C 9杂环基，而杂环烷基，杂环烯基，杂芳基，杂环残基可以具有多达6个杂环原子，氨基酸或其肽模拟物，所有上述残基均可任意取代，或为H.

65. 发明申请

WO2003016335A2 IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS OF LEGUMAIN 审中-公开
标题翻译： LEGUMAIN的不可逆半胱氨酸蛋白酶抑制剂
公开(公告)号：WO2003016335A2
公开(公告)日：2003-02-27
申请号：PCT/EP2002/008202
申请日：2002-07-23
申请人： PROBIODRUG AG , NIESTROJ, Andrè , HEISER, Ulrich , GERHARTZ, Bernd , HOFFMANN, Matthias , DEMUTH, Hans-Ulrich
发明人： NIESTROJ, Andrè , HEISER, Ulrich , GERHARTZ, Bernd , HOFFMANN, Matthias , DEMUTH, Hans-Ulrich
IPC分类号： C07K5/00
CPC分类号： C07K5/0202 , A61K38/00 , C07K5/0806
摘要： Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects.
摘要翻译：（I）和（II）所代表的化合物用于抑制半胱氨酸蛋白酶legumain以调节受试者中的相关疾病状态。

66. 发明申请

WO0234242A3 METHOD FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS 审中-公开
标题翻译：治疗神经病学和神经病学疾病的方法
公开(公告)号：WO0234242A3
公开(公告)日：2003-01-30
申请号：PCT/EP0112478
申请日：2001-10-29
申请人： PROBIODRUG AG , VON HOERSTEN STEPHAN , HOFFMANN TORSTEN , DEMUTH HANS-ULRICH , KUEHN-WACHE KERSTIN , FRIEDRICH DANIEL
发明人： VON HOERSTEN STEPHAN , HOFFMANN TORSTEN , DEMUTH HANS-ULRICH , KUEHN-WACHE KERSTIN , FRIEDRICH DANIEL
IPC分类号： A61K45/00 , A61K31/00 , A61K31/17 , A61K31/40 , A61K31/426 , A61K38/00 , A61K38/17 , A61P1/14 , A61P9/12 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/36 , A61P29/02 , A61P43/00 , C07D277/04 , A61K31/425
CPC分类号： A61K31/17 , A61K31/00 , A61K31/40 , A61K31/426 , A61K38/17 , A61K2300/00
摘要： The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable attractin inhibitor causes the reduction of activity in the enzyme attraction or in isoforms thereof in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY(1-36), NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects.
摘要翻译：本发明公开了一种治疗性处理动物（包括人）用于心身，抑郁和神经精神疾病如焦虑，抑郁，失眠，精神分裂症，癫痫，痉挛和慢性疼痛的方法。施用合适的吸引蛋白抑制剂导致哺乳动物脑中的酶吸引力或其同种型的活性降低，并导致神经肽Y（NPY）和类似底物的降解降低的因果结果。这种治疗将导致功能活跃的神经元NPY（1-36）的浓度降低或延迟。由于产生的内源性NPY（1-36）的稳定性增加，NPY活性延长，从而导致其它功能活性的NPY Y1受体活性，从而促进抗抑郁，抗焦虑，镇痛，抗高血压和其他神经功能。

67. 发明申请

WO0114318A3 NEW EFFECTORS OF DIPEPTIDYL PEPTIDASE IV FOR TOPICAL USE 审中-公开
标题翻译： NEW效应物的二肽基肽酶IV用于局部使用
公开(公告)号：WO0114318A3
公开(公告)日：2001-11-01
申请号：PCT/EP0008118
申请日：2000-08-20
申请人： PROBIODRUG GES FUER ARZNEIM , DEMUTH HANS ULRICH , HOFFMANN TORSTEN , SCHLENZIG DAGMAR , HEISER ULRICH
发明人： DEMUTH HANS-ULRICH , HOFFMANN TORSTEN , SCHLENZIG DAGMAR , HEISER ULRICH
IPC分类号： A61K9/06 , A61K8/49 , A61K8/72 , A61K9/08 , A61K9/107 , A61K9/12 , A61K9/70 , A61K9/72 , A61K31/765 , A61K38/00 , A61K47/48 , A61P1/02 , A61P3/00 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07K5/037 , C07K5/06 , C07K5/072 , C07K5/083 , C07K5/113 , C07K7/06 , C07K7/08 , C08G65/329 , A61K31/425 , A61K38/06 , C07D277/04 , C07K7/02
CPC分类号： C07K5/06078 , A61K38/00 , C07K5/06104 , C07K5/0806 , C07K7/08 , C08G65/329
摘要： The invention relates to compounds of general formula (I), wherein A represents an amino acid with at least one functional group in the side chain; while B is a chemical compound covalently bound to a functional group of the side chain of A, namely oligopeptide with a chain length of up to 20 amino acids with the exception of glycine homopolymers which have up to 6 glycine monomers or polyethylene glycols with molar masses of up to 20000 g/mole; C represents a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group which is amide bonded. These compounds can be used to topically influence the activity of dipeptidyl Peptidase IV.
摘要翻译：本发明涉及通式（I）其中A是具有在侧链中的至少一种官能基团的氨基酸的化合物，B是共价结合的官能团的侧链的，即，具有链长寡肽的化学化合物达除由多达6 Glycinmonomeren的具有至多至20000克/摩尔的摩尔质量甘氨酸的均聚物或聚乙二醇20个氨基酸，C是噻唑烷，吡咯烷，Cyanopyrrolidin-，羟脯氨酸，Dehydroprolin-或哌啶的酰胺键基团与是存在的。这些化合物可以被用于局部影响二肽基肽酶IV的活性。

68. 发明申请

WO2010133620A3 MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE 审中-公开
标题翻译：携带QPCTL基因的锁定突变的小鼠模型
公开(公告)号：WO2010133620A3
公开(公告)日：2011-01-27
申请号：PCT/EP2010056862
申请日：2010-05-19
申请人： PROBIODRUG AG , SCHILLING STEPHAN , GRAUBNER SIGRID , SEDLMEIER REINHARD , KOCH BIRGIT , CYNIS HOLGER , STEPHAN ANETT , DEMUTH HANS-ULRICH
发明人： SCHILLING STEPHAN , GRAUBNER SIGRID , SEDLMEIER REINHARD , KOCH BIRGIT , CYNIS HOLGER , STEPHAN ANETT , DEMUTH HANS-ULRICH
IPC分类号： A01K67/027
CPC分类号： A01K67/0276 , A01K2217/03 , A01K2227/105 , A01K2267/0356 , A01K2267/0368
摘要： The present invention provides a knock- out non-human animal, in particular a mouse carrying a QPCTL knock- out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL- related diseases.
摘要翻译：本发明提供了敲除非人动物，特别是携带QPCTL敲除突变的小鼠。本发明另外提供各自的细胞和细胞系以及用于评估影响QPCTL的试剂的方法和组合物，用于治疗与QPCTL相关的疾病的组合物。

69. 发明申请

WO2010009987A2 DIAGNOSTIC ANTIBODY ASSAY 审中-公开
标题翻译：诊断性抗体测定
公开(公告)号：WO2010009987A2
公开(公告)日：2010-01-28
申请号：PCT/EP2009/058803
申请日：2009-07-10
申请人： PROBIODRUG AG , DEMUTH, Hans-Ulrich , SCHILLING, Stephan , KLEINSCHMIDT, Martin , GANS, Kathrin , REISENAUER-SCHAUPP, Anita , RAHFELD, Jens-Ulrich , KAMPFER, Sonja
发明人： DEMUTH, Hans-Ulrich , SCHILLING, Stephan , KLEINSCHMIDT, Martin , GANS, Kathrin , REISENAUER-SCHAUPP, Anita , RAHFELD, Jens-Ulrich , KAMPFER, Sonja
IPC分类号： A61K39/00 , C07K16/18
CPC分类号： C07K16/18 , A61K39/3955 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/92 , G01N33/6896 , G01N2333/4709 , G01N2800/2814 , G01N2800/2821 , G01N2800/387
摘要： The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
摘要翻译：本发明涉及用于诊断淀粉样变性，特别是阿尔茨海默氏病和相关方面的新型诊断测定法。具体而言，提供单克隆抗体和抗体测定。

70. 发明申请

WO2009034158A3 TRANSGENIC MICE 审中-公开
标题翻译：转基因大会
公开(公告)号：WO2009034158A3
公开(公告)日：2009-06-25
申请号：PCT/EP2008062117
申请日：2008-09-12
申请人： PROBIODRUG AG , SCHILLING STEPHAN , CYNIS HOLGER , DEMUTH HANS-ULRICH , GRAUBNER SIGRID , JAGLA WOLFGANG
发明人： SCHILLING STEPHAN , CYNIS HOLGER , DEMUTH HANS-ULRICH , GRAUBNER SIGRID , JAGLA WOLFGANG
IPC分类号： C07K14/47 , A01K67/027 , C12N9/10 , C12N15/85
CPC分类号： C12Y203/02005 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0312 , C07K14/4711 , C07K2319/00 , C12N9/104 , C12N15/8509 , C12N2830/008
摘要： The present invention provides a transgenic non-human animal, in particular a transgenic mouse encoding Aß peptide proteins, which have been implicated in Aß peptide-related diseases. The present invention additionally provides cells and cell lines comprising transgenes encoding for Aß peptide. The present invention further provides methods and compositions for evaluating agents that affect Aß peptide, for use in compositions for the treatment of Aß peptide-related diseases.
摘要翻译：本发明提供了转基因非人动物，特别是编码Aβ肽蛋白的转基因小鼠，其涉及Aβ肽相关疾病。本发明另外提供了包含编码Aβ肽的转基因的细胞和细胞系。本发明还提供了用于评估影响Aβ肽的试剂的方法和组合物，用于治疗Aβ肽相关疾病的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式